In this podcast, Dr Hochhaus discusses the significance of the ASCEMBL trial, and proposes the question of how to eliminate persisting leukemic stem cells (LSCs) in CML.

Dr Hochhaus discusses the use of asciminib versus bosutinib for the treatment of patients with CML-CP previously given ≥2 TKIs.

Zhenya Tang, MD, PhD, discusses the findings and clinical significance of a study he led on the use of FISH to identify chromosomal abnormalities in patients with CML.

Gary Lyman, MD, comments on the clinical significance and findings of a study he co-conducted on the link between generic imatinib availability and trends in TKI use among patients with CML.

Matt Kalaycio, MD, discusses how treatment for CML has evolved in the past 2 decades, and touches on the IRIS trial, which greatly impacted the treatment landscape for this disease.

Elisabetta Abruzzese, MD, PhD, discusses the history of research pertaining to patients with CML who are pregnant or planning to start a family.

Sonia Amin Thomas, PharmD, BCOP, discusses data regarding the safety and efficacy of bosutinib therapy for patients with chronic-phase CML.

Jorge Cortes, MD, discusses results from an interim analysis of the OPTIC trial, evaluating the association between ponatinib exposure, efficacy, and safety with response-based dose reduction in CML.